Biocryst Pharmaceuticals reported $-74196000 in Net Income for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
DBV Technologies DBVT:US -16706000 3.03M
Alnylam Pharmaceuticals ALNY:US $ -240.34M 18.12M
Biocryst Pharmaceuticals BCRX:US $ -74.2M 56.42M
Chemocentryx CCXI:US $ -38.61M 1.92M
Chugai Pharma 4519:JP Y 131775M 32934M
Daiichi Sankyo 4568:JP Y -27345M 59198M
Enanta Pharmaceuticals ENTA:US $ -33.59M 3.48M
Gilead Sciences GILD:US $ 19M 363M
Glaxosmithkline GSK:US $ 1802M 1053M
GlaxoSmithKline GSK:LN 1802M 1053M
Intra Cellular Therapies ITCI:US $ -72.12M 13.62M
IONIS PHARMACEUT IONS:US $ -65.17M 289.78M
Karyopharm Therapeutics KPTI:US $ -41399000 80.12M
Mirati Therapeutics MRTX:US $ -188.39M 11.23M
Neurocrine Biosciences NBIX:US $ 13.9M 21.2M
Novavax NVAX:US $ 203.41M 1049.69M
Ptc Therapeutics PTCT:US $ -126.73M 16.54M
Regeneron Pharmaceuticals REGN:US $ 973.5M 1255.5M
Sarepta Therapeutics SRPT:US $ -105.02M 16.96M
Ultragenyx Pharmaceutical RARE:US $ -152.32M 29.86M
Vertex Pharmaceuticals VRTX:US $ 762.1M 8.01M
YTE INCY:US $ 37.99M 525.86M